Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion–Positive Non–Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial

PURPOSE: Selpercatinib, a highly selective, potent RET inhibitor with CNS activity, demonstrated sustained antitumor responses and intracranial activity in patients with RET-altered advanced non–small-cell lung cancer (NSCLC) in the global LIBRETTO-001 and Chinese LIBRETTO-321 trials. We report a pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Ying, Huang, Dingzhi, Zhou, Jianying, Zhou, Chengzhi, Sun, Yuping, Wu, Lin, Guo, Ye, Jingxin, Shao, Zhang, Wanli, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10309543/
https://www.ncbi.nlm.nih.gov/pubmed/37315261
http://dx.doi.org/10.1200/PO.22.00708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10309543/
https://www.ncbi.nlm.nih.gov/pubmed/37315261
http://dx.doi.org/10.1200/PO.22.00708

Ejemplares similares